Is the bull market for biotechs slowing?

Biosimilars generic

Biotechs have long been through to be a strong play for investors, with the Nasdaq Biotechnology index gaining about 150 percent over the past three years. But analysts are worried about new political challenges to drug pricing and China’s slowed growth. There are some that believe that biotech’s days of being an investor darling are over.

Read the source article at The Boston Globe

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>